14th Jul 2009 07:00
|
Press Release |
14 July 2009 |
e-Therapeutics plc
("e-Therapeutics" or "the Company")
Notice of Final Results
e-Therapeutics plc (AIM: ETX), the systems biology drug discovery company, today advises that it will announce its final results for the year ended 31 January 2009 on Monday 27 July 2009.
An analyst briefing given by the Company's management will be held at 9:30am that morning at the offices of Abchurch Communications, 100 Cannon Street, London EC4N 6EU.
- Ends -
|
For more information: |
|
|
e-Therapeutics plc |
www.etherapeutics.co.uk |
|
Malcolm Young |
+44 (0) 191 233 1317 |
|
Nominated Advisor & Broker: Canaccord Adams Ltd |
www.canaccordadams.com |
|
Robert Finlay / Henry Fitzgerald-O'Connor |
+44 (0) 20 7050 6500 |
|
Media enquiries: Abchurch Communications |
www.abchurch-group.com |
|
Heather Salmond / Stephanie Cuthbert / Simone Alves |
+44 (0) 20 7398 7700 |
Notes to Editors
e-Therapeutics plc is a systems biology drug discovery company. It has developed proprietary computational systems to swiftly and accurately analyse and predict how medicines interact with cells in the body. This optimises the probability of identifying drug candidates with desirable efficacy and low toxicity. The Company applies its novel, systematic approach to three areas of activity:
|
discovery of new drugs; |
|
|
discovering novel uses for existing drugs; and |
|
|
analysis of the interactions between different drugs. |
Amongst e-Therapeutics' pipeline of compounds in development are novel antibiotics that have been shown to kill the "superbug" MRSA, and a novel cancer chemotherapy that has been shown to kill malignant cells at safe doses in a very short time. Other candidate therapies in development are targeted at atherosclerosis, asthma and depression. The Company is currently in negotiation with a number of pharmaceutical companies, and is progressing the preclinical and clinical development of these products.
For further information on e-Therapeutics visit www.etherapeutics.co.uk.
Related Shares:
ETX.L